Lumos Pharma (LUMO)
(Delayed Data from NSDQ)
$1.76 USD
-0.04 (-2.22%)
Updated Jul 29, 2024 03:58 PM ET
After-Market: $1.79 +0.03 (1.70%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Lumos Pharma, Inc [LUMO]
Reports for Purchase
Showing records 41 - 60 ( 77 total )
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Non-Deal Roadshow (NDR) Highlights; OraGrowtH210 Trial Data in Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
1Q21 Results; Phase 2b Data for LUM-201 Expected Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
KOL Event Focused on Pediatric Growth Hormone Deficiency and LUM-201
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
A New Look at LUM-201 Data is Encouraging for the Phase 2b Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
4Q20 Results; OraGrowtH210 Trial Continues to Enroll, Data Expected Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Highlights From Non-Deal Roadshow (NDR); Raising PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
3Q20 Results; Phase 2b OraGrowtH210 Study Launched in Pediatric Growth Hormone Deficiency Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Oral Beats Everything, Transferring Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department